Mechanism of VB-111 in Treating Ovarian Cancer: Bradley Monk, MD, FACOG, FACS


Bradley Monk, MD, FACOG, FACS, discusses the mechanism of VB-111 in patients with ovarian cancer.

This content originally appeared on our sister site, OncLive.

VB-111 is a targeted anticancer viral gene therapy that is based on a non-replicating, non-integrating adenovirus 5 vector that contains a transgene expressed solely in angiogenic blood vessels.

OncLive spoke with Bradley Monk, MD, FACOG, FACS, a gynecologic oncologist at Arizona Oncology, about the mechanism of action of VB-111 in patients with ovarian cancer.

The agent has a dual mechanism of action, Monk says. The agent targets endothelial cells, which causes vascular disruption and results in tumor starvation, and induces immune response through local inflammation, Monk concludes.

Related Videos
Carlos Moraes, PhD, on Understanding Mitochondrial Mutations for Neurodegenerative Diseases
Aude Chapuis, MD, an associate professor in the Translational Science and Therapeutics Division at Fred Hutch Cancer Center
Amar Kelkar, MD, a stem cell transplantation physician at the Dana-Farber Cancer Institute
Frederick “Eric” Arnold, PhD
David Porter, MD
Raj Chovatiya, MD, PhD
Mitchell Horwitz, MD
Marcus Conant, MD
Shalini Shenoy, MD, MBBS, the director of the Stem Cell Transplant & Cellular Therapy Program at St. Louis Children’s Hospital
N. Nora Bennani, MD
© 2024 MJH Life Sciences

All rights reserved.